[HTML][HTML] Interplay between natural killer cells and anti-HER2 antibodies: perspectives for breast cancer immunotherapy
A Muntasell, M Cabo, S Servitja, I Tusquets… - Frontiers in …, 2017 - frontiersin.org
Overexpression of the human epidermal growth factor receptor 2 (HER2) defines a subgroup
of breast tumors with aggressive behavior. The addition of HER2-targeted antibodies (ie, …
of breast tumors with aggressive behavior. The addition of HER2-targeted antibodies (ie, …
[HTML][HTML] Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations
…, MP Schroeder, A Vivancos, A Rovira, I Tusquets… - Genome medicine, 2018 - Springer
While tumor genome sequencing has become widely available in clinical and research
settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we …
settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we …
Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors
…, I Álvarez, M Muñoz, MÁ Seguí, I Tusquets… - Critical reviews in …, 2014 - Elsevier
In spite of recent advances in the treatment of metastatic breast cancer, this disease remains
essentially incurable. Anthracyclines and taxanes have been widely demonstrated to be the …
essentially incurable. Anthracyclines and taxanes have been widely demonstrated to be the …
[HTML][HTML] Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer
F Rojo, J Garcia-Parra, S Zazo, I Tusquets… - Annals of oncology, 2012 - Elsevier
Background Poly(ADP-ribose)polymerase-1 (PARP-1) is a highly promising novel target in
breast cancer. However, the expression of PARP-1 protein in breast cancer and its …
breast cancer. However, the expression of PARP-1 protein in breast cancer and its …
Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/HER2-negative breast cancer—the evaluating …
…, D Magazzù, R De Fato, P Valagussa, I Tusquets - JAMA …, 2018 - jamanetwork.com
Importance Studies of neoadjuvant chemotherapy regimens using anthracyclines followed
by taxanes have reported a doubling of pathological complete remission (pCR) rates …
by taxanes have reported a doubling of pathological complete remission (pCR) rates …
[HTML][HTML] Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision …
…, ML Limon, AS Munoz, M Martin, I Tusquets… - Annals of …, 2012 - Elsevier
Background This study examined the impact of the Recurrence Score (RS) in Spanish breast
cancer patients and explored the associations between clinicopathological markers and …
cancer patients and explored the associations between clinicopathological markers and …
Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance
…, L Garrigos, X Nogues, I Tusquets - Therapeutic …, 2015 - journals.sagepub.com
Aromatase inhibitors (AIs) are routinely used in the adjuvant treatment of women with hormone
receptor-positive early breast cancer. Patients who receive AIs have an increased risk of …
receptor-positive early breast cancer. Patients who receive AIs have an increased risk of …
[HTML][HTML] Activation of nuclear factor-κ B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients
C Montagut, I Tusquets, B Ferrer… - Endocrine-related …, 2006 - erc.bioscientifica.com
The nuclear factor (NF)-κB system is a promising anticancer target due to its role in oncogenesis
and chemoresistance in preclinical models. To provide evidence in a clinical setting on …
and chemoresistance in preclinical models. To provide evidence in a clinical setting on …
A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma
Purpose: To evaluate the efficacy of treatment with the aromatase inhibitor letrozole in breast
cancer patients segregated with respect to DNA polymorphisms of the aromatase gene …
cancer patients segregated with respect to DNA polymorphisms of the aromatase gene …
Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study
…, A Diez-Perez, J Albanell, I Tusquets… - Breast cancer research …, 2011 - Springer
Aromatase inhibitor (AI)-associated arthralgia limits adherence to therapy in breast cancer.
The pathophysiology may involve vitamin D status. We wished to establish the optimal …
The pathophysiology may involve vitamin D status. We wished to establish the optimal …